OLIO: A phase II, randomised, non-comparative two-arm trial of neoadjuvant chemotherapy plus either olaparib or olaparib + durvalumab in young, pre-menopausal women with HRD-enriched, HR-positive, HER2-negative early breast cancer

  • Harris, Marion (Primary Chief Investigator (PCI))

Project: Research

Project Details

StatusActive
Effective start/end date28/08/24 → 27/08/29